drugset

drugset / Trial / NCT00252746

ZD6474 Phase IIa Dose Finding Multicentre Study

NCT00252746 ↗

Phase 2 Completed 53 enrolled Genzyme, a Sanofi Company

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively

Timeline

Start: 2004-12
Primary completion: 2007-01
Completion: 2007-01

Publications

Background Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vandetanib	Small molecule	100 mg	Oral
Subject	Vandetanib	Small molecule	200 mg	Oral
Subject	Vandetanib	Small molecule	300 mg	Oral

Indications